""Lateral Pharma commenced operations in May 2015 to repurpose LAT8881, a Phase 2 orally-available compound with extensive toxicology and human safety data, into new high potential indications""
PER Price at posting:
0.9¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)